# Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT00577694** · PHASE1 · TERMINATED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** clofarabine
- **DRUG:** gemtuzumab ozogamicin

## Key facts

- **NCT ID:** NCT00577694
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2010-07
- **Final completion:** 2015-08
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** funding unavailable
- **Last updated:** 2015-10-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00577694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00577694, "Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00577694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*